Events
On March 29, the general office of the State Council issued the “14th five year plan” for the development of traditional Chinese medicine, which defined the objectives, tasks and key measures for the development of traditional Chinese medicine during the 14th Five Year Plan period, insisted on promoting the modernization and industrialization of traditional Chinese medicine, and promoted the high-quality development of traditional Chinese medicine and its entry into the world.
Comments
Clearly put forward 15 major development indicators, implement the status of traditional Chinese medicine in epidemic prevention and control, and promote the healthy and high-quality development of traditional Chinese medicine industry. One “binding” development index: “in 2025, the proportion of fever clinics in three-level public traditional Chinese medicine hospitals and hospitals with integrated traditional Chinese and Western Medicine (excluding traditional Chinese medicine specialized hospitals) will reach 100%”. At present, the global covid-19 pneumonia epidemic is still in a pandemic state, and the state actively encourages traditional Chinese medicine to play a role in the prevention and control of the epidemic. 14 “expected” development indicators. Among them, the number of TCM hospitals will reach 6300 by 2025, an increase of 818 compared with 2020; The number of practicing (Assistant) doctors of traditional Chinese medicine per 1000 population will reach 0.62 by 2025, an increase of 29% over 2020; The number of beds in public TCM hospitals per 1000 population will reach 0.85 by 2025, an increase of 25% over 2020.
Improve the price of traditional Chinese medicine and medical insurance policies. The plan points out that the prepared pieces and preparations of traditional Chinese medicine processed and used by medical institutions shall be priced independently, and those that meet the conditions shall be included in the payment scope of basic medical insurance according to procedures; Support insurance companies and traditional Chinese medicine institutions to cooperate in health management services, and encourage commercial insurance institutions to develop insurance products such as traditional Chinese medicine for the treatment of diseases. The further clarification of medical insurance policy will inject new vitality into the development of follow-up traditional Chinese medicine products.
Promote the optimization of registration and approval of innovative traditional Chinese medicine. The plan lists “reforming and improving the registration management of traditional Chinese medicine” as the main task, optimizes the clinical evidence system of traditional Chinese medicine, establishes the evidence system of registration and evaluation of traditional Chinese medicine, and explores the registration management of traditional Chinese medicine preparations. In 2021, a total of 12 innovative traditional Chinese medicine drugs have been approved by the State Food and Drug Administration for listing. 2021 has also become the year in which innovative traditional Chinese medicine drugs have been approved the most in recent five years.
International sales may become a new increment in the development of traditional Chinese medicine. The plan puts forward clear development objectives, “actively promote the open development of traditional Chinese medicine”, and “promote the overseas registration and application of traditional Chinese medicine products”. At present, the opening and development of traditional Chinese medicine has achieved positive results, which has spread to 196 countries and regions, and the total import and export trade of traditional Chinese medicine commodities has increased significantly. Chinese traditional Chinese medicine enterprises are also constantly practicing the principles and policies of “going global”, opening up overseas mainstream markets and opening up a new situation of national sales of traditional Chinese medicine.
Support the development of traditional Chinese medicine health industry. The aggravation of population aging and the increase of the incidence of chronic diseases have brought considerable market demand for the “prevention of diseases” of traditional Chinese medicine. The plan lists “highlighting the characteristic advantages of traditional Chinese medicine in health services” as the main task, and continues to carry out traditional Chinese medicine health management for key groups such as children aged 0-36 months and the elderly over 65 years old, so as to gradually improve the coverage rate. With the support of national policies, the improvement of health awareness and the promotion of consumption, the consumption attribute of the traditional Chinese medicine industry has been enhanced and helped the market increase in volume.
Recommended subject matter
We are optimistic about the development of traditional Chinese medicine industry: national policies support the development of traditional Chinese medicine industry. At the same time, the use of traditional Chinese medicine has played an important role in epidemic prevention and control. With the promotion of health awareness and consumption upgrading, the demand for traditional Chinese medicine is gradually released, and the certainty of industry development in the future is enhanced. It is suggested to increase the investment and allocation of traditional Chinese medicine.
It is suggested to pay attention to: China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) , Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) , GUSHENG hall, Jianmin Pharmaceutical Group Co.Ltd(600976) , Henan Lingrui Pharmaceutical Co.Ltd(600285) , etc.
Risk tips
Risk of recurrent outbreaks; High risk of channel inventory; The price rise of some products is less than the expected risk; The improvement of corporate governance is lower than the expected risk
